RxDoctor Payments Data

Stefan McNamara

Physician Assistant · Chehalis, WANPI 1962020925

Payments from drug & device makers

$1,109in general payments, 2019–2025

Across 50 payments — averaging $22.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$367
  • Novo Nordisk$161
  • Medical Device Business Services, Inc.$123
  • Teva Pharmaceuticals USA, Inc.$60
  • GSK$57
  • Xeris Pharmaceuticals, Inc.$38
  • plus $304 from 12 others

What the payments were for

  • Food & beverage$98689%
  • Education$12311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,109 in reported general payments places this provider in the 85th percentile of 2,741 physician assistant providers in Washington.

See all physician assistant providers in Washington

Medicare billing

Part B allowed, 2024
$5,152
Medicare patients
59
Services billed
110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide89$125,690
EliquisApixaban76$95,412
FarxigaDapagliflozin Propanediol59$71,359
JardianceEmpagliflozin43$69,493
TrulicityDulaglutide32$50,815
MounjaroTirzepatide27$33,623
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$28,153
MyrbetriqMirabegron13$18,197
JanuviaSitagliptin Phosphate18$17,550
XareltoRivaroxaban18$17,241
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$14,074
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$11,617
SymbicortBudesonide/Formoterol Fumarate27$8,301
Gabapentin165$5,518
Albuterol Sulfate HfaAlbuterol Sulfate119$3,973

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$161$125,69089 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$367$107,813110 claims
PfizerEliquis$35$95,41276 claims
Lilly USA, LLCTrulicity, Mounjaro$30$84,43859 claims
Boehringer IngelheimJardiance, Stiolto Respimat$21$83,56760 claims
Johnson & JohnsonXarelto$20$17,24118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,741 physician assistant providers in Washington.

Other physician assistant in Chehalis

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →